VENENUM Biodesign

VENENUM Biodesign is a drug discovery company focused on advancing drug discovery programs at our novel targets to Pre-Clinical Drug Candidates, and seeking partners for clinical development. Our most advanced programs are in Clostridium difficile (inhibitors of CDAD) and agonists of TGR5 for T2DM. We have Lead compounds progressing through Lead Optimization. Our dual business model allows us to focus internally on our research programs and develop partnerships.

VENENUM Biodesign…

• was established with the mission of improving patients' lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes (GPCRs, enzymes, NHRs etc.). Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies.
• utilizes state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 5.5 million ECLiPS compound collection, protein engineering and production, cellular reagent generation, structural biology, medicinal chemistry, and in vivo models for our own platforms. We offer access to these capabilities, to academic institutions, non-profits, research organizations, and pharmaceutical companies.
• is a company within the Genesis Biotechnology Group (GBG) located conveniently in Hamilton, New Jersey, and is easily accessible to other academic medical centers, biotech and pharmaceutical companies in the New York/ New Jersey/ Pennsylvania area.
• has collaborative research arrangements with several for-profit and not-for-profit groups and will consider additional collaborative relationships.